Healthcare

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has become one of the more closely followed newcomers in the obesity-drug arms race, and its shares closed down 6.51% at $13.94 at last closing. For a clinical-stage biotech that only recently went public, sharp daily swings are par for …

Micro-cap biotech stocks can lurch on the thinnest of volumes, and Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a textbook example. Shares closed up 8.29% at $2.22 at last closing, a jump that has drawn eyes to this obscure name, but the story is less about …

Few 2026 biotech debutants have arrived with as much momentum as Latigo Biotherapeutics. The non-opioid pain developer priced one of the year's larger clinical-stage offerings in August, drew a wall of bullish analyst coverage within weeks, and now commands aMarket Valuewell above a billion …

A gain in one of 2026's higher-profile biotech IPOs put Veradermics, Incorporated (NYSE:MANE) back in focus in September 2026, as the hair-loss specialist closed up 0.85% at $98.97 at last closing. The move was modest in percentage terms but notable given the company's multibillion-dollar …

Medline Inc. (NASDAQ:MDLN) arrived on the public markets late in 2025 as one of the largest healthcare listings in years, giving investors a rare pure-play stake in the medical-supply backbone of hospitals and care facilities. Nearly a year on, shares closed up 0.43% at …

Functional Brands, Inc (OTC:MEHA) sits at the speculative edge of the health-and-wellness market, a former Nasdaq hopeful now trading for a fraction of a cent. The nutraceutical and supplement company has spent the past year pushing an ambitious slate of product launches and corporate …

MiniMed Group, Inc (NASDAQ:MMED) has drawn fresh attention after its shares held largely steady in a September 2026 session, closing up a modest 0.27% at $22.50. Unlike the many clinical-stage names crowding the healthcare tape, MiniMed is an established diabetes-technologyBusinesswith billions in annual revenue, …